Vertex Pharmaceuticals Statistics

Total Valuation

FRA:VX1 has a market cap or net worth of EUR 97.33 billion. The enterprise value is 89.03 billion.

Market Cap	97.33B
Enterprise Value	89.03B

Important Dates

The next estimated earnings date is Monday, August 4, 2025.

Earnings Date	Aug 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	256.80M
Shares Outstanding	n/a
Shares Change (YoY)	-1.20%
Shares Change (QoQ)	-0.38%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	256.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	23.24
PS Ratio	9.48
PB Ratio	6.38
P/TBV Ratio	7.03
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 21.95, with an EV/FCF ratio of -76.97.

EV / Earnings	-97.31
EV / Sales	9.38
EV / EBITDA	21.95
EV / EBIT	23.63
EV / FCF	-76.97

Financial Position

The company has a current ratio of 2.65, with a Debt / Equity ratio of 0.10.

Current Ratio	2.65
Quick Ratio	2.12
Debt / Equity	0.10
Debt / EBITDA	0.35
Debt / FCF	-1.32
Interest Coverage	189.98

Financial Efficiency

Return on equity (ROE) is -5.64% and return on invested capital (ROIC) is 14.73%.

Return on Equity (ROE)	-5.64%
Return on Assets (ROA)	11.77%
Return on Invested Capital (ROIC)	14.73%
Return on Capital Employed (ROCE)	23.08%
Revenue Per Employee	1.68M
Profits Per Employee	-149,989
Employee Count	6,100
Asset Turnover	0.47
Inventory Turnover	4.79

Taxes

In the past 12 months, FRA:VX1 has paid 637.19 million in taxes.

Income Tax	637.19M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -13.44% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-13.44%
50-Day Moving Average	400.26
200-Day Moving Average	427.39
Relative Strength Index (RSI)	37.36
Average Volume (20 Days)	75

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.38

Income Statement

In the last 12 months, FRA:VX1 had revenue of EUR 10.27 billion and -914.93 million in losses. Loss per share was -3.55.

Revenue	10.27B
Gross Profit	5.45B
Operating Income	4.08B
Pretax Income	-277.75M
Net Income	-914.93M
EBITDA	4.24B
EBIT	4.08B
Loss Per Share	-3.55

Full Income Statement

Balance Sheet

The company has 5.74 billion in cash and 1.53 billion in debt, giving a net cash position of 8.98 billion.

Cash & Cash Equivalents	5.74B
Total Debt	1.53B
Net Cash	8.98B
Net Cash Per Share	n/a
Equity (Book Value)	15.26B
Book Value Per Share	59.39
Working Capital	5.76B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -906.97 million and capital expenditures -249.80 million, giving a free cash flow of -1.16 billion.

Operating Cash Flow	-906.97M
Capital Expenditures	-249.80M
Free Cash Flow	-1.16B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 53.09%, with operating and profit margins of 39.71% and -8.91%.

Gross Margin	53.09%
Operating Margin	39.71%
Pretax Margin	-2.70%
Profit Margin	-8.91%
EBITDA Margin	41.30%
EBIT Margin	39.71%
FCF Margin	n/a

Dividends & Yields

FRA:VX1 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.20%
Shareholder Yield	n/a
Earnings Yield	-0.94%
FCF Yield	-1.19%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:VX1 has an Altman Z-Score of 13.24 and a Piotroski F-Score of 2.

Altman Z-Score	13.24
Piotroski F-Score	2